PMID- 36540317
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221222
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 12
DP  - 2022 Dec
TI  - "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection.
PG  - e32548
LID - 10.7759/cureus.32548 [doi]
LID - e32548
AB  - Although the "original antigenic sin" (OAS) effects have been predicted against 
      new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
      only a few pieces of evidence are available regarding its impact on the safety 
      and effectiveness of coronavirus disease 2019 (COVID-19) vaccines. This article 
      aims to provide an immunological explanation for the delayed side effects of a 
      SARS-CoV-2 vaccine during an episode of natural infection. We reported a case of 
      a 39-year-old male healthcare worker who complained about pruritus and discomfort 
      around the injection site of an inactivated SARS-CoV-2 vaccine administrated 18, 
      17, and 13 months earlier. Those symptoms resembled the side effects previously 
      experienced with one of the booster doses, and a sole erythematous papule was 
      also documented. The patient was diagnosed with COVID-19 one or two days after 
      noticing these local signs and symptoms, and high serum titers of immunoglobulin 
      M (IgM) and immunoglobulin E (IgE) were found five weeks after the onset, along 
      with SARS-CoV-2-specific immunoglobulin G (IgG) antibodies. Therefore, the OAS 
      might be a plausible phenomenon to consider in individuals immunized with 
      inactivated vaccines and exposed secondarily to a wild virus with antigenic 
      variations.
CI  - Copyright (c) 2022, Castillo-Aleman et al.
FAU - Castillo-Aleman, Yandy M
AU  - Castillo-Aleman YM
AD  - Department of Immunology, Abu Dhabi Stem Cells Center, Abu Dhabi, ARE.
FAU - Villegas-Valverde, Carlos A
AU  - Villegas-Valverde CA
AD  - Laboratory of Immunology, Abu Dhabi Stem Cells Center, Abu Dhabi, ARE.
FAU - Ventura-Carmenate, Yendry
AU  - Ventura-Carmenate Y
AD  - Department of Immunology, Abu Dhabi Stem Cells Center, Abu Dhabi, ARE.
FAU - Suarez-Formigo, Gisela M
AU  - Suarez-Formigo GM
AD  - Laboratory of Immunology, Abu Dhabi Stem Cells Center, Abu Dhabi, ARE.
FAU - Bencomo-Hernandez, Antonio A
AU  - Bencomo-Hernandez AA
AD  - Laboratory of Immunology, Abu Dhabi Stem Cells Center, Abu Dhabi, ARE.
LA  - eng
PT  - Case Reports
DEP - 20221215
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9756105
OTO - NOTNLM
OT  - adverse events
OT  - antigenic variation
OT  - covid-19
OT  - sars-cov-2
OT  - vaccine
COIS- The primary author (YMCA) is also the subject of the case reported. All authors 
      judged this autobiographical report to be ethically feasible as the clinical 
      course reported was verified, and the competing interests were declared during 
      the Journal submission.
EDAT- 2022/12/22 06:00
MHDA- 2022/12/22 06:01
PMCR- 2022/12/15
CRDT- 2022/12/21 02:08
PHST- 2022/12/15 00:00 [accepted]
PHST- 2022/12/21 02:08 [entrez]
PHST- 2022/12/22 06:00 [pubmed]
PHST- 2022/12/22 06:01 [medline]
PHST- 2022/12/15 00:00 [pmc-release]
AID - 10.7759/cureus.32548 [doi]
PST - epublish
SO  - Cureus. 2022 Dec 15;14(12):e32548. doi: 10.7759/cureus.32548. eCollection 2022 
      Dec.